-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Ming Yan Sells 20,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock
Ming Yan Sells 20,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) CTO Ming Yan sold 20,000 shares of the firm's stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $11.03, for a total transaction of $220,600.00. Following the completion of the transaction, the chief technology officer now directly owns 7,946,833 shares in the company, valued at approximately $87,653,567.99. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Ming Yan also recently made the following trade(s):
Get Cytek Biosciences alerts:- On Monday, December 19th, Ming Yan sold 20,000 shares of Cytek Biosciences stock. The shares were sold at an average price of $10.38, for a total transaction of $207,600.00.
- On Monday, November 21st, Ming Yan sold 20,000 shares of Cytek Biosciences stock. The shares were sold at an average price of $14.66, for a total transaction of $293,200.00.
Cytek Biosciences Price Performance
Cytek Biosciences stock opened at $11.01 on Friday. Cytek Biosciences, Inc. has a 12-month low of $7.38 and a 12-month high of $16.05. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of -1,101.00 and a beta of 0.06. The firm's fifty day moving average price is $11.77 and its 200 day moving average price is $12.97.
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.01). Cytek Biosciences had a positive return on equity of 0.94% and a negative net margin of 0.47%. The firm had revenue of $40.48 million for the quarter, compared to analysts' expectations of $43.36 million. Analysts forecast that Cytek Biosciences, Inc. will post 0.04 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its holdings in Cytek Biosciences by 20.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 394,034 shares of the company's stock worth $5,800,000 after acquiring an additional 66,045 shares in the last quarter. Advisory Research Inc. acquired a new position in shares of Cytek Biosciences in the 3rd quarter valued at about $614,000. State Street Corp boosted its holdings in shares of Cytek Biosciences by 17.6% in the 3rd quarter. State Street Corp now owns 2,030,253 shares of the company's stock valued at $29,885,000 after buying an additional 304,433 shares during the period. Algert Global LLC boosted its holdings in shares of Cytek Biosciences by 116.5% in the 3rd quarter. Algert Global LLC now owns 46,055 shares of the company's stock valued at $678,000 after buying an additional 24,785 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its holdings in shares of Cytek Biosciences by 9.2% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 69,822 shares of the company's stock valued at $1,028,000 after buying an additional 5,865 shares during the period. 49.48% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, Piper Sandler lifted their price target on shares of Cytek Biosciences from $16.00 to $18.00 in a research note on Monday, November 14th.
About Cytek Biosciences
(Get Rating)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Read More
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
賽特克生物科學公司(納斯達克代碼:CTKB-GET Rating)首席技術官嚴明在1月19日週四的一次交易中出售了20,000股該公司股票。這些股票以11.03美元的平均價格出售,總成交金額為220,600.00美元。交易完成後,首席技術官現在直接擁有該公司7,946,833股,價值約87,653,567.99美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可在美國證券交易委員會網站。
明言最近還進行了以下交易:
到達Cytek生物科學警報:- 12月19日,星期一,明言出售了兩萬股賽特克生物科學公司的股票。這些股票以10.38美元的平均價格出售,總成交金額為207,600.00美元。
- 11月21日,星期一,明言出售了2萬股Cytek Biosciences股票。這些股票以14.66美元的平均價格出售,總成交額為293,200.00美元。
Cytek Bioscions性價比
Cytek Biosciences的股票上週五開盤報11.01美元。Cytek Biosciences,Inc.的12個月低點為7.38美元,12個月高位為16.05美元。該公司市值14.8億美元,本益比為-1101.00,貝塔係數為0.06。該公司的50日移動均線價格為11.77美元,200日移動均線價格為12.97美元。
賽特克生物科學公司(納斯達克代碼:CTKB-GET Rating)最近一次發佈季度收益報告是在11月9日星期三。該公司公佈本季度每股收益(EPS)為0.01美元,低於普遍預期的0.02美元(0.01美元)。Cytek Biosciences的股本回報率為正0.94%,淨利潤率為負0.47%。該公司當季營收為4,048萬美元,高於分析師預期的4,336萬美元。分析師預測,Cytek Biosciences,Inc.本財年每股收益將為0.04美元。機構資金流入和流出
幾家對沖基金最近增持或減持了該股。紐約梅隆銀行(Bank Of New York Mellon Corp)在第三季度增持了Cytek Biosciences 20.1%的股份。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有394,034股該公司股票,價值5,800,000美元,此前該公司在上一季度增持了66,045股。諮詢研究公司在第三季度收購了Cytek Biosciences股票的新頭寸,價值約614,000美元。道富集團在第三季度增持了Cytek Biosciences的股票17.6%。道富銀行目前持有該公司2,030,253股股票,價值29,885,000美元,在此期間又購買了304,433股。阿爾蓋特全球有限責任公司在第三季度將其持有的賽特克生物科學公司的股票增加了116.5%。阿爾伯特全球有限責任公司現在擁有46,055股該公司的股票,價值678,000美元,在此期間又購買了24,785股。最後,瑞銀資產管理美洲公司(UBS Asset Management America Inc.)在第三季度增持了Cytek Biosciences的股票9.2%。瑞銀資產管理美洲公司(UBS Asset Management America Inc.)目前持有69,822股該公司股票,價值1,028,000美元,在此期間又購買了5,865股。49.48%的股票由機構投資者和對沖基金持有。
華爾街分析師也加入進來
另外,派珀·桑德勒在11月14日星期一的一份研究報告中將Cytek Biosciences的目標股價從16.00美元上調至18.00美元。
關於賽特克生物科學公司
(獲取評級)
Cytek Biosciences,Inc.是一家細胞分析解決方案公司,提供細胞分析工具,促進生物醫學研究和臨床應用的科學進步。它提供極光和北極光系統,這是一種光譜流動細胞儀,通過利用來自多個雷射的螢光信號來區分單個細胞上的螢光標記來提供細胞分析;以及極光細胞分選系統,它利用全光譜圖譜技術進一步拓寬了細胞分析的潛在應用。
閱讀更多內容
- 免費獲取StockNews.com關於Cytek生物科學的研究報告(CTKB)
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車?
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
接受Cytek生物科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cytek Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧